Emily Bodnar
Stock Analyst at H.C. Wainwright
(4.11)
# 1,614
Out of 4,644 analysts
677
Total ratings
39.6%
Success rate
7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Bodnar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACRV Acrivon Therapeutics | Maintained: Buy | $19 | $1.72 | +1,004.65% | 25 | Aug 13, 2026 | |
| TRAX First Tracks Biotherapeutics | Maintained: Buy | $44 → $57 | $46.13 | +23.56% | 5 | Aug 13, 2026 | |
| NXTC NextCure | Maintained: Buy | $20 | $8.17 | +144.80% | 16 | Aug 12, 2026 | |
| AGEN Agenus | Rated: Buy | $30 → $25 | $6.90 | +262.32% | 41 | Aug 11, 2026 | |
| AUTL Autolus Therapeutics | Maintained: Buy | $10 | $2.12 | +371.70% | 8 | Aug 11, 2026 | |
| NKTX Nkarta | Rated: Buy | $16 → $14 | $2.39 | +485.77% | 31 | Aug 11, 2026 | |
| OLMA Olema Pharmaceuticals | Reiterated: Buy | $38 → $36 | $10.44 | +244.83% | 47 | Aug 11, 2026 | |
| SANA Sana Biotechnology | Maintained: Buy | $7 | $3.77 | +85.68% | 27 | Aug 11, 2026 | |
| COAG Hemab Therapeutics Holdings | Rated: Buy | $52 → $60 | $53.48 | +12.19% | 4 | Aug 11, 2026 | |
| PPBT Purple Biotech | Rated: Buy | $30 → $17 | $1.48 | +1,048.65% | 20 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $45 → $42 | $31.78 | +32.16% | 11 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 | $11.53 | +203.56% | 10 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 | $28.96 | +55.39% | 21 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $3.80 | +163.16% | 12 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $0.4699 | +964.06% | 39 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $1.57 | - | 14 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $77 → $78 | $49.50 | +57.58% | 13 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $52 → $55 | $34.21 | +60.77% | 24 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $46 → $52 | $17.59 | +195.62% | 45 | Jul 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.35 | - | 27 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $0.3752 | +3,098.29% | 5 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 | $11.36 | +208.10% | 26 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $31 | $2.70 | +1,048.15% | 15 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 | $1.61 | +1,452.80% | 26 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $55 → $66 | $56.98 | +15.83% | 20 | Mar 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $20 | $0.8239 | +2,327.48% | 21 | Mar 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $5.19 | +246.82% | 1 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.002 | - | 24 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $55.78 | $4.74 | +1,076.80% | 34 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $160 | $2.35 | +6,708.51% | 32 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.37 | n/a | 22 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 | $2.33 | n/a | 5 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.66 | n/a | 6 | May 22, 2024 |
Acrivon Therapeutics
Aug 13, 2026
Maintained: Buy
Price Target: $19
Current: $1.72
Upside: +1,004.65%
First Tracks Biotherapeutics
Aug 13, 2026
Maintained: Buy
Price Target: $44 → $57
Current: $46.13
Upside: +23.56%
NextCure
Aug 12, 2026
Maintained: Buy
Price Target: $20
Current: $8.17
Upside: +144.80%
Agenus
Aug 11, 2026
Rated: Buy
Price Target: $30 → $25
Current: $6.90
Upside: +262.32%
Autolus Therapeutics
Aug 11, 2026
Maintained: Buy
Price Target: $10
Current: $2.12
Upside: +371.70%
Nkarta
Aug 11, 2026
Rated: Buy
Price Target: $16 → $14
Current: $2.39
Upside: +485.77%
Olema Pharmaceuticals
Aug 11, 2026
Reiterated: Buy
Price Target: $38 → $36
Current: $10.44
Upside: +244.83%
Sana Biotechnology
Aug 11, 2026
Maintained: Buy
Price Target: $7
Current: $3.77
Upside: +85.68%
Hemab Therapeutics Holdings
Aug 11, 2026
Rated: Buy
Price Target: $52 → $60
Current: $53.48
Upside: +12.19%
Purple Biotech
Aug 10, 2026
Rated: Buy
Price Target: $30 → $17
Current: $1.48
Upside: +1,048.65%
Aug 7, 2026
Rated: Buy
Price Target: $45 → $42
Current: $31.78
Upside: +32.16%
Aug 7, 2026
Maintained: Buy
Price Target: $35
Current: $11.53
Upside: +203.56%
Aug 6, 2026
Maintained: Buy
Price Target: $45
Current: $28.96
Upside: +55.39%
Aug 6, 2026
Maintained: Buy
Price Target: $10
Current: $3.80
Upside: +163.16%
Aug 6, 2026
Maintained: Buy
Price Target: $5
Current: $0.4699
Upside: +964.06%
Aug 5, 2026
Maintained: Hold
Price Target: n/a
Current: $1.57
Upside: -
Aug 4, 2026
Rated: Buy
Price Target: $77 → $78
Current: $49.50
Upside: +57.58%
Jul 30, 2026
Maintained: Buy
Price Target: $52 → $55
Current: $34.21
Upside: +60.77%
Jul 24, 2026
Rated: Buy
Price Target: $46 → $52
Current: $17.59
Upside: +195.62%
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $2.35
Upside: -
May 15, 2026
Maintained: Buy
Price Target: $12
Current: $0.3752
Upside: +3,098.29%
May 15, 2026
Maintained: Buy
Price Target: $35
Current: $11.36
Upside: +208.10%
May 8, 2026
Maintained: Buy
Price Target: $31
Current: $2.70
Upside: +1,048.15%
Apr 2, 2026
Maintained: Buy
Price Target: $25
Current: $1.61
Upside: +1,452.80%
Mar 30, 2026
Maintained: Buy
Price Target: $55 → $66
Current: $56.98
Upside: +15.83%
Mar 30, 2026
Rated: Buy
Price Target: $20
Current: $0.8239
Upside: +2,327.48%
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $18
Current: $5.19
Upside: +246.82%
Nov 17, 2025
Maintained: Hold
Price Target: n/a
Current: $0.002
Upside: -
Oct 13, 2025
Maintained: Buy
Price Target: $55.78
Current: $4.74
Upside: +1,076.80%
Sep 26, 2025
Maintained: Buy
Price Target: $160
Current: $2.35
Upside: +6,708.51%
Apr 29, 2025
Rated: Hold
Price Target: n/a
Current: $3.37
Upside: n/a
Mar 31, 2025
Maintained: Buy
Price Target: $8
Current: $2.33
Upside: n/a
May 22, 2024
Rated: Hold
Price Target: n/a
Current: $2.66
Upside: n/a